Introduction
The tendency towards hypercalcaemia in thyrotoxicosis has been documented.l Reported incidence of hypercalcaemia in thyrotoxicosis is between 8-22%.2'3 Usually the hypercalcaemia is mild but occasionally it is severe enough to be symptomatic or even life-threatening, and urgent treatment specifically directed to the hypercalcaemia is therefore occasionally desirable.
Previous studies"14-6 have shown the hypercalcaemia of thyrotoxicosis to be due primarily to increased bone resorption, although relative immobilization during hospitalization may sometimes play a contributory role. 3 Intravenous infusion of aminohydroxypropylidene diphosphonate (APD) has been shown by ourselves and others7-10 to be effective and safe in treating malignancy-induced hypercalcaemia by inhibiting bone resorption. The calcaemia was made and substantiated biochemically (Table I) Oral propranolol in conventional dosage as used in the second case for control of thyrotoxic symptoms is ineffective by itself in lowering serum calcium.'13"4 The calcium lowering effect of antithyroid drugs in both cases was slow but sustained. The first and second cases were still hypercalcaemic after 10 and 19 days of treatment respectively (Figures 1 and 2 ) in accord with a previous report15 that normalization of serum calcium concentration might take 2 to 8 weeks of antithyroid therapy. In contrast, infusions of APD rapidly normalized the serum calcium concentration in 1 respectively by inhibition of bone resorption as indicated by the rapid fall of urinary calcium and hydroxyproline to normal ( Figures I and 2 ) with transient pyrexia in case 2 as the only side effect. Relief of symptoms parallelled the falls in serum calcium. In contrast to intravenous calcitonin '6 and propranolol,3'13 the normalized serum calcium concentration was sustained without further infusion of APD. This could be due both to the more prolonged calcium lowering action of APD, as described up to 8 days in a study10 on hypercalcaemia of malignancy, and to the continued use of antithyroid drugs which has a slower but sustained effect. In both cases vomiting was a prominent feature of the hypercalcaemia and delayed the diagnosis in the first case.
The hypoalbuminaemia and hyperphosphataemia noted in both cases (Table I) are recognized features of thyrotoxicosis.1 The alkaline phosphatase seen in case 1 was inappropriately high to be derived from bone and a hepatic origin, as suggested by concomitant elevation of other liver enzymes, was subsequently confirmed by an alkaline phosphatase isoenzyme study. A normocalcaemic relapse 3 months later with similar elevation of liver enzymes suggests association of the two conditions. A causal relationship between jaundice and thyrotoxicosis has previously been reported. 1 6 In conclusion, one or two infusions of APD used concomitantly with volume repletion and antithyroid drugs is an effective and safe method of controlling significant and symptomatic hypercalcaemia in thyrotoxicosis.
